- Abbott India‘s net income for the third quarter was 3.61 billion rupees, surpassing estimates of 3.3 billion rupees.
- Year-over-year net income growth was 16%.
- Revenue reached 16.1 billion rupees, exceeding the estimated revenue of 15.81 billion rupees and marking a 12% increase from the previous year.
- Total costs were reported at 12 billion rupees, also up by 12% year-over-year.
- Following the earnings release, Abbott India‘s shares increased by 2.9% to 26,892 rupees, with 13,209 shares traded.
- Market analysts show a positive outlook with 4 buy ratings, no hold ratings, and 1 sell rating.
A look at Abbott India Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 5 | |
| Growth | 4 | |
| Resilience | 5 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 4.0 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Abbott India Limited’s long-term outlook appears promising based on Smartkarma Smart Scores, which evaluate various aspects of the company. With high scores in Dividend and Resilience, investors may find Abbott India to be a stable and rewarding option. The company’s strong dividend score indicates a consistent track record of distributing profits to shareholders, while its resilience score reflects the ability to withstand market volatility and economic downturns.
Furthermore, Abbott India‘s above-average scores in Growth and Momentum suggest potential for expansion and positive stock price performance in the foreseeable future. Despite a moderate score in Value, the company’s overall outlook, bolstered by its diverse range of pharmaceutical and medical products, remains favorable for investors seeking a reliable and growing investment opportunity.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
